• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/2/21 4:15:36 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials
    Get the next $SENS alert in real time by email
    SC 13G/A 1 tm218449d1_sc13ga.htm SC 13G/A
    CUSIP No. 81727U105 SCHEDULE 13G/A Page  1  of  7 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

      

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)* 

     

    Senseonics Holdings, Inc.

     


    (Name of Issuer)

     

    Common Stock, $0.001 par value

     

    (Title of Class of Securities)

     

    81727U105

     

    (CUSIP Number)

     

    February 26, 2021

     

    (Date of Event Which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 81727U105 SCHEDULE 13G/A Page  2  of  7 

     

    1. NAMES OF REPORTING PERSONS
    Roche Finance Ltd
       
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

      (b) ¨
       
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland

     

    NUMBER OF 5. SOLE VOTING POWER 0
    SHARES    
    BENEFICIALLY    
    OWNED BY 6.

    SHARED VOTING POWER 17,523,209

     

    EACH    
    REPORTING 7.

    SOLE DISPOSITIVE POWER 0

     

    PERSON WITH    
      8.

    SHARED DISPOSITIVE POWER 17,523,209

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    17,523,209

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (See Instructions) ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.7%

    12.

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

           

     

     

     

    CUSIP No. 81727U105 SCHEDULE 13G/A Page  3  of  7 

     

     

    1. NAMES OF REPORTING PERSONS
    Roche Holding Ltd
       
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

      (b) ¨
       
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland

     

    NUMBER OF 5. SOLE VOTING POWER 0
    SHARES    
    BENEFICIALLY    
    OWNED BY 6.

    SHARED VOTING POWER 17,523,209

     

    EACH    
    REPORTING 7.

    SOLE DISPOSITIVE POWER 0

     

    PERSON WITH    
      8.

    SHARED DISPOSITIVE POWER 17,523,209

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    17,523,209

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (See Instructions) ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.7%

    12.

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

           

     

     

     

      

    CUSIP No. 81727U105 SCHEDULE 13G/A Page  4   of  7 

     

     

    Item 1(a).Name of Issuer:

     

    Senseonics Holdings, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    20451 Seneca Meadows Parkway, Germantown, Maryland 20876-7005

     

    Item 2.

     

    (a) Name of Person Filing: Roche Finance Ltd and Roche Holding Ltd

     

    (b) Address or principal business office or, if none, residence:

     

    Roche Finance Ltd: Grenzacherstrasse 122, 4070 Basel, Switzerland.

     

    Roche Holding Ltd: Grenzacherstrasse 124, 4070 Basel, Switzerland.

     

    (c) Citizenship:

     

    Roche Finance Ltd: Switzerland

     

    Roche Holding Ltd: Switzerland

     

    (d) Title of Class of Securities: Common Stock, $0.001 par value.

     

    (e) CUSIP No.: 81727U105.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership:

     

    (a)Each of the Reporting Persons may be deemed to beneficially own 17,523,209 shares of Common Stock.*

     

    (b)Percent of Class: Each Reporting Person may be deemed to beneficially own 4.7%, based on 372,288,782 shares of Common Stock outstanding as of February 4, 2021, as reported in the Issuer’s Form S-3 Registration Statement effective February 16, 2021.*

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)       Sole power to vote or to direct the vote: 0.

     

    (ii)       Shared power to vote or to direct the vote: 17,523,209.

     

    (iii)       Sole power to dispose or to direct the disposition of: 0.

     

    (iv)       Shared power to dispose or to direct the disposition of: 17,523,209.

     

    *Roche Holding Ltd may be deemed to have beneficial ownership of the 17,523,209 shares directly beneficially owned by Roche Finance Ltd, its wholly-owned subsidiary.

     

     

     

    CUSIP No. 81727U105 SCHEDULE 13G/A Page  5  of  7 

     

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Roche Finance Ltd is a wholly-owned subsidiary of Roche Holding Ltd.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10.Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    CUSIP No. 81727U105 SCHEDULE 13G/A Page  6  of  7 

      

    SIGNATURE

     

     

    After reasonable inquiry and to the best of their knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 2nd day of March, 2021

     

      ROCHE FINANCE LTD
       
      By: /s/ Carole Nuechterlein
      Carole Nuechterlein, Authorized Signatory
       
       
      By: /s/ Beat Kraehenmann
      Beat Kraehenmann, Authorized Signatory
       
       
      ROCHE HOLDING LTD
       
      By: /s/ Beat Kraehenmann
      Beat Kraehenmann, Authorized Signatory
       
       
      By: /s/ Claudia Boeckstiegel
      Claudia Boeckstiegel, Authorized Signatory

     

     

     

     

    CUSIP No. 81727U105 SCHEDULE 13G/A Page  7  of  7 

     

     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13G/A and any future amendments thereto reporting each of the undersigned’s ownership of securities of the Issuer named herein, and hereby affirm that such Schedule 13G/A is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that he or it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G/A shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Exchange Act, nor is a joint venture for purposes of the Investment Company Act of 1940.

     

    Dated this 2nd day of March, 2021  

     

      ROCHE FINANCE LTD
       
      By: /s/ Carole Nuechterlein
      Carole Nuechterlein, Authorized Signatory
       
       
      By: /s/ Beat Kraehenmann
      Beat Kraehenmann, Authorized Signatory
       
       
      ROCHE HOLDING LTD
       
      By: /s/ Beat Kraehenmann
      Beat Kraehenmann, Authorized Signatory
       
       
      By: /s/ Claudia Boeckstiegel
      Claudia Boeckstiegel, Authorized Signatory

     

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Prince Douglas S was granted 17,069 shares, increasing direct ownership by 2% to 1,087,607 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    7/3/25 4:15:40 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Steven Edelman was granted 27,048 shares, increasing direct ownership by 2% to 1,263,001 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    7/3/25 4:15:32 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Roeder Douglas A was granted 30,987 shares, increasing direct ownership by 2% to 1,658,826 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    7/3/25 4:15:35 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics

    - Agreement with Senseonics to transfer commercial activities would integrate Eversense manufacturing and distribution to accelerate growth PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE:SENS). The companies are targeting to unite Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026, subject to a definitiv

    9/3/25 7:22:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Reports Second Quarter Financial Results

    Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.6 million in the second quarter of 2025, an increase of 37% versus the second quarter of 2024, driven by 79% new patient growth in the U.S. over prio

    8/6/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    H.C. Wainwright resumed coverage on Senseonics with a new price target

    H.C. Wainwright resumed coverage of Senseonics with a rating of Buy and set a new price target of $1.10

    6/2/25 8:54:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    SEC Filings

    View All

    SEC Form EFFECT filed by Senseonics Holdings Inc.

    EFFECT - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/19/25 12:15:16 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form 424B3 filed by Senseonics Holdings Inc.

    424B3 - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/18/25 4:36:27 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form DEF 14A filed by Senseonics Holdings Inc.

    DEF 14A - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/18/25 7:30:29 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Roeder Douglas A bought $37,500 worth of shares (75,000 units at $0.50), increasing direct ownership by 5% to 1,463,087 units (SEC Form 4)

    4/A - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/20/24 5:37:53 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Roeder Douglas A bought $135,500 worth of shares (325,000 units at $0.42), increasing direct ownership by 30% to 1,413,087 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/16/24 4:21:25 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Chief Financial Officer Sullivan Frederick T. bought $47,475 worth of shares (124,933 units at $0.38), increasing direct ownership by 5% to 2,478,844 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/12/24 7:04:14 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025. Management will hold a conference call to review the Company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by na

    7/16/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Reports First Quarter Financial Results

    Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.3 million in the first quarter of 2025CMS upda

    5/8/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials